Deutsche Bank’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-721
Closed -$272K 5576
2019
Q1
$272K Buy
+721
New +$242K ﹤0.01% 3818
2018
Q1
Hold
0
5659
2017
Q4
Sell
-392
Closed -$258K 5198
2017
Q3
$296K Buy
392
+191
+95% +$151K ﹤0.01% 3682
2017
Q2
$167K Buy
201
+58
+41% +$42.4K ﹤0.01% 4023
2017
Q1
$101K Sell
143
-43
-23% -$30.3K ﹤0.01% 3916
2016
Q4
$133K Sell
186
-7
-4% -$5.68K ﹤0.01% 3926
2016
Q3
$184K Buy
193
+24
+14% +$30.3K ﹤0.01% 3691
2016
Q2
$240K Buy
169
+26
+18% +$33.4K ﹤0.01% 3677
2016
Q1
$176K Hold
143
﹤0.01% 3722
2015
Q4
$184K Hold
143
﹤0.01% 3765
2015
Q3
$207K Buy
143
+52
+57% +$100K ﹤0.01% 3782
2015
Q2
$200K Buy
91
+79
+658% +$248K ﹤0.01% 3889
2015
Q1
$35K Sell
12
-13
-52% -$41.6K ﹤0.01% 4494
2014
Q4
$81K Buy
+25
New +$88.5K ﹤0.01% 4855
2014
Q3
Sell
-52
Closed -$199K 6136
2014
Q2
$199K Sell
52
-65
-56% -$245K ﹤0.01% 4130
2014
Q1
$474K Sell
117
-37
-24% -$165K ﹤0.01% 3373
2013
Q4
$569K Buy
154
+101
+191% +$383K ﹤0.01% 3015
2013
Q3
$209K Buy
53
+12
+29% +$90K ﹤0.01% 4100
2013
Q2
$401K Buy
+41
New +$454K ﹤0.01% 3312

Other funds holding FRTX

Deutsche Bank's FRTX Position: Q2 2019 in Review

Deutsche Bank sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2019, closing a stake of 721 shares — an estimated $272K sold.

Deutsche Bank first reported a position in FRTX in Q2 2013 and held it in 18 quarters. The position peaked at $569K in Q4 2013. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2019.

  • Deutsche Bank reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Deutsche Bank sold 721 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $272K.
  • Deutsche Bank first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
  • Deutsche Bank's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $569K in Q4 2013.
  • 22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Deutsche Bank's 13F filing for Q2 2019, filed 14 Aug 2019.